Skip to main content
English
Català
Español
Company
Overview & History
Team
Join Oryzon
Epigenetics
Histone Code Hypothesis
Modulator Enzymes
LSD1 & Disease
Technology Platforms
Scientific Publications by Oryzon
Therapeutic Programs
Strategy
LSD1 & Cancer
Oryzon's Pipeline
Collaborative Research
Collaborative Projects
For Patient
Patient Information
Shareholders and Investors
Investor Information and News
Share Information
Events & Presentations
Financial Information & Downloads
Analyst Coverage
Corporate Governance
Corporate Social Responsibility
News & Press Releases
Contact
General Contact
Investor Contact
Email Alerts
News
Archive
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
News & Press Releases
3 February 2017
Oryzon received Best Business Practices Award for Innovation
30 January 2017
ORYZON to outline development of Lysine Specific Demethylase Inhibitors for Oncological and Neurodegenerative Diseases at Keystone Symposia on Epigenetics and Human Disease
25 January 2017
ORYZON to present ORY-2001 preliminary top line Phase I clinical data at the 13th International Conference on Alzheimer’s and Parkinson’s Diseases in Vienna, Austria
16 January 2017
ORYZON Announces Expansion of its Scientific Advisory Board
9 January 2017
ORYZON Announces First Patient Dosed in Phase 1 Trial of the LSD1 inhibitor RG6016 in Small Cell Lung Cancer (SCLC)
4 January 2017
ORYZON in San Francisco during the 35th Annual J.P. Morgan Healthcare Conference
21 December 2016
ORYZON Receives a New 0.8 M USD Public Grant to Explore New Indications for Epigenetic Inhibitors
6 December 2016
ORYZON Announces Encouraging Top-line Results from Phase I-IIA Clinical Trial in Acute Leukemia of RG6016 (ORY-1001) at the American Society of Hematology 2016 Annual Meeting
14 November 2016
ORYZON to Present Clinical Data on LSD1 Inhibitor ORY-1001 at ASH 2016
7 November 2016
ORYZON Announces Exercise of Warrants by Alzheimer’s Drug Discovery Foundation (ADDF)
Pages
« first
‹ previous
…
4
5
6
7
8
9
10
11
12
…
next ›
last »